Futura Medical PLC has launched a formal sale process for its business or assets, alongside a £1.6 million fundraise to support ongoing negotiations. The company believes its current market value undervalues its portfolio, which includes the Eroxon erectile dysfunction gel and the WSD4000 female sexual health project, both with significant sales potential. The board is exploring options such as asset sales, licensing, or a full company sale, with non-binding offers due by 2 October. The fundraise will extend the company's cash runway to February 2027, allowing time to complete the strategic review amid challenges like slower-than-expected Eroxon sales and upcoming costly clinical studies for WSD4000.
Solana spot ETFs in the US have recorded 11 consecutive days of positive net inflows, adding $10.9 million on September 1 alone, pushing total inflows to $1.35 billion and assets under management to $1.39 billion. Despite a slight 3% price dip to aro...
The U.S. economy continued its expansion in August, driven by healthy private-sector demand and sustained business investment, particularly in AI infrastructure. Household incomes grew alongside a stable labor market, supporting overall economic grow...
Ripple's XRP price has pulled back to $1.32 after a strong 72% rally in August, pressured by US-Iran geopolitical tensions and broader crypto market weakness. Despite the price drop, XRP-focused ETFs in the US saw $14 million inflows on Tuesday, push...
Howmet Aerospace's stock dropped sharply after Elon Musk announced SpaceX and Tesla's entry into turbine blade production, but this selloff is viewed as an overreaction. Howmet's competitive edge lies in its technical expertise, long-term contracts, ...
Nomura's digital asset unit Laser Digital has partnered with Keyring Network to create institutional fixed income lending and borrowing markets on the decentralized finance platform Euler Finance. Laser Digital will oversee risk governance while Keyr...
